文献速递免疫规划传染病防控与疫情报告

HIV感染者对强化乙肝疫苗接种方案的真实世界应答

Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions.
PubMed 文献 · Vaccine · 2019-04-10

本研究在西班牙大学医院纳入332例HIV感染者,给予0、1、2月三剂双倍剂量乙肝疫苗,77.1%应答。女性和非吸烟者应答率更高,CD4+/CD8+比值≥0.67及基线HIV-RNA≤50 copies/mL为独立预测因素。

要点

  • 三剂双倍剂量乙肝疫苗在HIV感染者中应答率77.1%。
  • 女性和非吸烟者应答率更高。
  • CD4+/CD8+比值≥0.67和基线HIV-RNA≤50 copies/mL为独立预测因素。

核心结论

  • 加速三剂双倍剂量乙肝疫苗在HIV感染者中应答率较高但仍不理想,应考虑第四剂。

研究设计与样本

  • 西班牙大学医院真实世界研究,纳入332例HBV血清阴性HIV感染者,0、1、2月接种三剂双倍剂量(40 µL)乙肝疫苗。

主要发现

  • 332例中256例(77.1%)对乙肝疫苗应答。
  • 应答者中位CD4+/CD8+比值为0.75(IQR 0.52-1.01),非应答者为0.61(IQR 0.38-0.84),p=0.002。
  • 女性(AOR 6.240,95%CI 1.954-19.925,p=0.002)、非吸烟(AOR 2.151,95%CI 1.243-3.721,p=0.006)、CD4+/CD8+比值≥0.67(AOR 2.580,95%CI 1.209-5.505,p=0.014)和基线HIV-RNA≤50 copies/mL(AOR 2.049,95%CI 1.098-3.824,p=0.024)为独立预测因素。

关键数值与推荐

  • 应答定义为末剂乙肝疫苗后1-12个月HBV表面抗体浓度≥10 IU/L。

临床怎么用

  • 对HIV感染者接种乙肝疫苗可采用加速三剂双倍剂量方案,并评估第四剂必要性。
  • 接种前关注CD4+/CD8+比值、HIV-RNA水平、性别和吸烟状态以预测应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-infected patients are at risk of hepatitis B virus (HBV) coinfection, however, respond worse to HBV vaccination (HBV-V) than immunocompetent adults. This study aimed to determine the response to reinforced HBV-V in HIV-infected subjects under real-life conditions. METHODS: HIV-infected patients followed at a Spanish University Hospital who were seronegative for HBV and who received three double-doses (40 µL) of HBV-V at 0, 1 and 2 months were included. Response to HBV-V was defined as HBV surface antibody concentration of ≥10 IU/L 1-12 months after the last HBV-V dose. RESULTS: Of 332 patients included in the study, 256 (77.1%) showed response to HBV-V. Median (interquartile range) CD4+/CD8+ ratio among the responders was 0.75 (0.52-1.01) versus 0.61 (0.38-0.84) among the non-responders (p = 0.002). Independent predictors for HBV-V response were: female gender [adjusted odds ratio (AOR): 6.240; 95% confidence interval (95%CI): 1.954-19.925; p = 0.002]; non-smoking [AOR: 2.151; 95%CI: 1.243-3.721; p = 0.006]; a CD4+/CD8+ ratio ≥0.67 [AOR: 2.580; 95%CI: 1.209-5.505; p = 0.014] and baseline HIV-RNA ≤50 copies/mL [AOR: 2.049; 95%CI: 1.098-3.824; p = 0.024]. CONCLUSION: Accelerated administration of three double-doses results in considerable high, however still suboptimal, response rates to HBV-V in HIV-infected patients in the clinical practice. A fourth dose should be considered.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, et al. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine. 2019. PMID: 30981625. doi:10.1016/j.vaccine.2019.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。